Integrins and Melanoma Progression
Tumor (or neoplastic) progression is one of the crucial events in the development of cancer. It is defined as the acquisition of permanent, irreversible, and qualitative changes of one or more characteristics in a neoplasm and its precursor lesions (Nowell 1986). Confronted with selective pressure imposed by host defense and/or therapy, tumor progression favors relentless emergence of new subpopulations with enhanced growth and metastatic capacities, creating tumor heterogeneity (Fidler 1988). Tumor heterogeneity is based on both genetic and epigenetic changes and on differences in development and maturation of the tumor cell population. A better understanding of the pathogenesis of neoplastic progression is likely to provide new clues for diagnosis and therapy aimed at the aggressive tumor cell populations.
KeywordsEpidermal Growth Factor Receptor Integrin Expression Melanoma Progression Fibronectin Receptor Cell BioI
Unable to display preview. Download preview PDF.
- Aresu O, Nicolò G, Allavena G, Melchiori A, Schmidt J, Kopp JB, d’Amore E, Chader GJ, Albini A (1991) Invasive activity, spreading on and chemotactic response to laminin are properties of high but not low metastatic mouse osteosarcoma cells. Invest Metastasis 11: 2–13Google Scholar
- Chen YQ, Nelson KK, Fitzgerald LA, Honn KV (1991) Detection of αllbβ3 integrin in melanoma cells and its correlation with tumor cell metastasis. Proc Am Assoc Cancer Res 32: 3–3Google Scholar
- Erle DJ, Ruegg C, Sheppard D, Pytela R (1990) Complete amino acid sequence of an integrin β subunit (β7) identified in leucocytes. J Biol Chem 266: 11009–11016Google Scholar
- Herlyn M, Clark WH Jr, Rodeck U, Mancianti ML, Jambrosic J, Koprowski H (1987) Biology of tumor progression in human melanocytes. Lab Invest 66: 461–474Google Scholar
- Komoriya A, Green LJ, Mervic M, Yamada SS, Yamada KM, Humphries MJ (1991) The minimal essential sequence for a major cell type-specific adhesion site (CS1) within the alternatively spliced type III connecting segment domain of fibronectin is leucine-aspartic acid-valine. J Biol Chem 266: 15075–15079PubMedGoogle Scholar